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Basophils and mast cells are important effectorcells ofinflammation and in par-
ticular of acute allergic reactions. Basophils can be activated to release inflamma-
torymediatorsby IgE-dependent andIgE-independent stimuli (1-4). The mediator
profile produced by basophils strongly depends upon the agonist used to activate
thecells (4a). Forexample, crosslinking ofhigh-affinity IgE-receptors by an antigen,
anti-IgE or anti-receptor antibodies leads to the release ofpreformed mediators
from granule stores, like histamine and proteolytic enzymes, and also results in the
activation ofenzymes(phospholipase[s] and 5-lipoxygenase) responsiblefor the gener-
ation ofleukotriene C4 (LTC4),' a very potent lipid mediator and smooth muscle
contractant (6). Conversely, the anaphylatoxin C5a, which at low concentrations is
a potent inducer ofbasophil degranulation, does not activate basophils to produce
bioactivelipids. These observationsclearly indicate that degranulation and the gener-
ation ofthe arachidonic acid metabolite LTC4 are dissociated events and therefore
controlled by different mechanisms.
Granulocyte/macrophage colony-stimulating factor (GM-CSF) is a pluripotent
growth factor for myeloid bone marrow precursors (7, 8), but more recent studies
demonstrated that this cytokine also enhances the function (in particular cytotox-
icity and oxygen radical release) ofmature inflammatory effector cells, like mono-
cytes, eosinophils, andneutrophils(PMN) (9-13). Studies from ourlaboratorydemon-
strated that PMN sequentially exposed to GM-CSF and the chemotactic peptides
C5aor FMLP release relatively large amounts ofLTB4 and LTB4 metabolites, while
neither peptide alone triggers the formation of these lipid mediators (14). Preex-
posure ofPMN to GM-CSF also results in a strong enhancement ofchemotactic
peptide-dependentgeneration ofplatelet-activatingfactor, anotherpotent lipid medi-
ator (15). From these experiments we concluded that GM-CSF not only enhances
effector cell functions, but also qualitatively changes in the mediator profile ofthe
neutrophils triggered by diverse agonists.
These observations suggested that other growth-promoting cytokines may also
modify the mediator profile of mature leukocytes, and we thus studied the effects
of IL-3 on blood basophils. IL-3 stimulates the growth of early progenitor cells of
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all the hematopoietic lineages (reviewed in reference 16) . In contrast to GM-CSF,
there is little information about effects of IL-3 on mature white cells (16) . It is con-
ceivable that, upon maturation, leukocytes lose receptors for this cytokine . How-
ever, IL-3 isknown topromote the growth ofrelativelymature histamine containing
cells inbonemarrow cultures, suggesting that circulating basophils could retain IL-3
receptors .
In this articlewe show that IL-3 strongly affects the function ofmature basophils .
It enhances the stimulus-dependent release ofhistamine. In particular, IL-3 enables
basophils to produce large quantities ofLTC4 in response to C5a, while neither pep-
tide alone triggers the generation of lipid mediators . This establishes a novel func-
tion of IL-3 and shows that the basophil mediator release profile can be modified
by a cytokine. This IL-3 effect might be important in the pathogenesis of immediate-
type hypersensitivity reactions, shock syndromes, and inflammation .
Materials and Methods
Blood Donor Selection. " Normal (nonatopic) donors were defined as individuals without a
history of immediate hypersensitivity reactions, normal IgE values, and negative skin tests
to common allergies (pollen, molds, pet dander, house dust, mites) . Atopic individuals had
positive skin tests andRAST tests to at least one allergen, allergic symptomatology, and normal
to high IgE levels .
CellPreparation .
￿
Blood from informed volunteers, anticoagulated with 10mM EI7TA, was
mixed with 0.25 volumes of6% dextran (Pharmacia, Uppsala, Sweden), and erythrocytes
were allowed to sediment at room temperature (RT). Leukocytes were pelleted by centrifuga-
tions (150 g, 20 min, RT) and suspended in HA buffer (20 mM Hepes, 125 mM NaCl, 5
mM KCI, 0.5mM glucose, and 0.025% human serum albumin [Calbiochem Behring Corp.,
La Jolla, CA]) . For most experiments, the cells were fractionated by Ficoll-Hypaque (Phar-
macia) density centrifugation (400 g, 40 min, RT) . The basophil-rich mononuclear cell layer
was harvested, washed three times (400 g, 10 min, 40C) in HA buffer, and finally suspended
inHACM buffer (HA buffer supplemented with 1 mM CaCl2 and 1 MM MgC12) at a cell
density of 2 .5 x 106 cells/ml .
In some experiments the leukocytes obtained after dextran sedimentation of erythrocytes
were fractionated by discontinuous Percoll (Pharmacia) density gradients . Isotonic Percoll
solutions with densities of 1.075, 1.070, 1.065, and 1.060 were made up by dilution of the
Percoll solution with Hepes buffer (washingbuffer without albumin) according to the manufac-
turer's specifications, and 2.5 ml ofeach was carefully layered into 15-ml plastic tubes . 1 ml
of N5 x 107 leukocytes in HA buffer was layered on the top of the Percoll gradient and cen-
trifuged for 30 min, 500 g at RT. The bands formed at the density interfaces and at the top
and the bottom of the gradient were harvested, washed three times (400 g, 10 min, 4°C),
and resuspended in HACM buffer.
Each cell fraction was stained with anti-Leu-5b (T cells), anti-Leu-16 (B cells), anti-Leu-
M3 (monocytes), and anti-Leu-11a (neutrophils/NK cells) (all from Becton Dickinson &Co.,
Mountain View, CA), and analyzed byFACS using an Ortho Cytofluorograph H50 (Ortho
Diagnostic Systems Inc., Westwood, MA). The cell fractions were also differentiated microscop-
ically (at least 400 cells per slide), after plating the cells on glass slides with a cytocentrifuge
and staining with May-Griinwald .
Stimuli.
￿
C5a was purified from yeast-activated human serum as described (17, 18) and
was homogeneous, as determined by amino acid analysis, SDS-PAGE, and microzone paper
electrophoresis at pH 8.6 . Human rIL-3 with bioactivity of 106 U/1.5 mg protein was a
generous gift ofDr. M . Schreier, Sandoz, Switzerland . 1 U/ml of IL-3 is defined as the con-
centration giving a 50% of maximal [ 3H]TdR incorporation in cultures of leukocytes from
chronic myeloid leukemia (CML) patients . The peptides were stored in concentrated stock
solutions at -70'C and diluted in HACM buffer before use . Stimuli were added to cells
in a 1 :100 volume ratio.KURIMOTO ET AL.
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Mediator Release Assay.
￿
Cells (2.5 x 106/ml/batch) in HACM buffer were warmed up to
37 °C for 10 min, before the addition of the peptide(s). The reaction was stopped after the
time indicated by placing the tubes in an ice bath, except for kinetic experiments, where
the cells were also cooled by the rapid addition of 1 vol of ice cold buffer. After centrifugation
(400 g, 10 min, 4°C), 500 Al of the supernatant was added to 500,1 of HACM buffer and
1 ml of 0.8 M HC104 and centrifuged again (600 g, 15 min). This supernatant was either
stored for up to 3 d at -30°C or immediately assayed for histamine using an automated
fluorimetric method (19). The other 500 1 .1 of the supernatants were stored for up to 1 wk
at -70°C before determination of sulidoleukotriene release by RIA (LTC4/LTD4/LTE4-RIA;
Amersham Corp., Arlington, IL) performed according to the recommendations ofthe supplier.
To validate the RIA experiments, HPLC analysis of LTC4, LTD4, and LTE4 was per-
formed as described (20). Briefly, sulfidoleukotrienes formed by Ficoll-Hypaque isolated cells
(2.5 x 107 cells/ml) were extracted (21) and analyzed by HPLC (20) using a U61K-injector,
model 510 pumps and a 990-plus photo-diode-array-detector (all from Waters Associates, Mil-
ford, MA). The column was a 25 x 0.4 cm Nucleosil C18-100-5 ,,m and the lipids were eluted
isocratically with methanol/3.5 mM ammonium acetate, pH 4.6, in H2O (75:25 vol/vol) at
a flow rate of 1 ml/min at RT. The HPLC analysis was calibrated with synthetic LTC4,
LTD4, and LTE4 (generous gift of Dr. Rockach, Merck-Frosst, Pointe Claire, Quebec,
Canada). Elution times were: LTC4, 5 .3 min; LTD4, 9.5 min; LTE4, 11.7 min. Cell-derived
LTC4 was further identified by UV spectroscopy and RIA in the corresponding HPLC frac-
tion. These experiments demonstrated that LTC4 formed by basophils was but very slowly
converted to LTE4 under the incubation conditions used in this study (4a). Nevertheless, a
RIA with an antibody with almost equal reactivity to LTC4, LTD4, and LTE4 was used, in
order not to underestimate sulfidoleukotriene generation due to conversion of LTC4 to LTE4.
Presentation of Data.
￿
Histamine release is expressed in percent of total histamine deter-
mined in cells lysed by perchloric acid (0.4 M final concentration). Total histamine release
represents histamine release without corrections. Specific histamine release represents total
histamine release minus the release obtained in the corresponding control samples incubated
with buffer alone. Sulfidoleukotriene release was initially expressed as nanograms ofsLT/2.5
x 106 cells. During the course of the studies, it was found that sLT release was related to
the numbers of basophil in the leukocyte preparations. Values of sLT generation were there-
fore converted to picograms ofsLT per nanogram of total cellular histamine, in order to cor-
rect for differences in basophil numbers in leukocytes obtained from different blood donors.
All experiments were performed at least three times in triplicates. Significance was deter-
mined by the Student's Mest.
Results
IL-3 Changes theMediator Profile ofBasophils Stimulated by C5a.
￿
In preliminary ex-
periments we determined the maximal effective concentration of C5a. Maximum
histamine release was obtained at C5a concentrations between 10-9 M and 10-8 M
with no further increase at higher C5a levels. In no instance did we observe the gener-
ation of LTC4 in basophils stimulated with C5a, even at 10' M (data not shown).
We then examined the effects ofmediator release ofIL-3 pretreatment. Fig. 1 shows
the results of 24 experiments performed with leukocytes ofnormal and atopic donors.
IL-3 alone did not significantly increase histamine release over that of spontaneous
release. The small increase of the mean release induced by IL-3 (Fig. 1, top) was
due to a very low continuous (>2 h) release, which was observed with the basophils
from some atopic donors. However, in the normal and most atopic donors, IL-3 did
not induce histamine release even at concentrations up to 1,000 ng/ml (datanot shown).
C5a alone is a potent inducer of basophil granule release in cells of all donors tested
so far (mean of 57% histamine release). This effect is more pronounced and less
variable when pure C5a rather than the partially purified C5 fragment (3, 4) is used.410
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FIGURE 1 .
￿
Change ofC5a-induced basophil mediator re-
lease profile by IL-3 . In 24 experiments, leukocyte from
different allergic and normal donors depleted ofPMN by
Ficoll-Hypaque were incubated after awarm-up period at
37°C for 10 min as follows : Spon: Cells were incubated in
buffer for 30 min (open columns) . IL-3 : Cells were incubated
with 10-9M IL-3 for 30 min (dotted columns) . C5a : After
incubation of the cells for 10 min, they there challenged with
10-s M C5a for 20 min (dashed columns) . IL-3-C5a : The
leukocytes were exposed to 10-9 M IL-3 for 10 min and
then triggered with 10-8M C5a for 20 min (black columns) .
Themean t SEMof mediators found in the supernatants
are shown . (Top) Histamine release (percent oftotal cell con-
tent ; mean = 93 t 3.9 ng/2 .5 x 106 cells) measured
fluorimetrically. (Bottom) sLT (LTC4/LTD4/LTE4) release
measured by RIA . sLTgeneration isexpressed as picograms
sLT/nanogram total histamine content ofthe respective cell
preparation, in order to correct for different basophil
numbers in leukocytes samples from different donors . The
three columns at the left represent the detection limit for sLT.
Preexposure of the cells to IL-3 significantly enhances (p< 0.001) the already marked
effect of C5a (N80% histamine release, corresponding to a 40% increase) .
The effect of IL-3 was dramatic when the generation of sulfidoleukotrienes (sLT;
LTC4/LTD4/LTE4) was determined . No production of LTC4 was observed with ei-
ther IL-3 or C5a alone, up to 1,000 ng/ml and 10-7 M, respectively (not shown),
with cells ofnormal and atopic donors (Fig. 1, bottom) . However, cells exposed to
IL-3 for 10 min and then stimulated with C5a produced very large quantities of
LTC4 (Fig . 1) . These results demonstrate that IL-3 not only enhances basophil
releasability, but "primes" basophils to respond to C5a challenge with the synthesis
of bioactive lipids . We believe that this qualitative change in the basophil mediator
profile is pathophysiologically much more important than just an enhancement of
a normally occurring degranulation response .
Concentration Dependence ofthe IL-3 Effect.
￿
The cells were incubated without or with
different concentrations of IL-3, and then either further incubated without addition
ofa second trigger(Fig . 2, open symbols), or stimulated with C5a (closed symbols) . The
results obtained from experiments performed with cells from an allergic (circles) and
a normal donor (triangles) show that the enhancement of histamine release and the
induction ofsLT synthesis by IL-3 priming was concentration dependent (Fig . 2) .
From the curves, an ED5o of 0.3-0.6 ng/ml (2-4 x 10-1 M = 0.2-0.4 U/ml) can
be estimated . A maximum effect was reached with 10 ng/ml, and thelevel of medi-
ator release remained constant even when IL-3 was used at 100-1,000 ng/ml (data
not shown) . Again, IL-3 alone over the entire dose range did not trigger sLT syn-
thesis nor did it induce histamine release substantially above that of controls (open
symbols) . The neglible, but statistically significant release ofhistamine by IL-3 alone
observed with cells from one donor (open circles) is an example of the donor vari-
ability discussed above . The experiments also further document that preexposure100
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FIGURE 2.
￿
Dose-responseof IL-3 priming. Cellswere
preincubated for 10 min with increasing doses ofIL-3
andthen stimulated with 10-8 M C5afor20 min (closed
symbols), or incubated with IL-3 alonefor 30 min (open
symbols). Each pointis mean t SD oftriplicates. (Circles)
atopic donor(total histamine = 112 t 1.3 ng/2.5 x 106
cells). (Triangles) normal donor (total histamine = 56
t 1.2 ng/2.5 x 106cells). (Top) Histamine release (per-
cent oftotal, without subtraction of spontaneous release).
(Bottom) sLTgeneration (picograms sLT/nanogram hista-
mine content ofcells). No further increase ofmediator
release occurs at IL-3 concentration of >10 ng/ml.
Where not shown, SD is smaller than the size of the
symbol.
ofbasophils to IL-3 is absolutely required for C5a-induced sLT synthesis, while the
effect ofIL-3 upon basophil degranulation is much less striking, C5a beingby itself
apotent inducer ofhistamine release. As shown in these two representative experi-
ments, there is no qualitative difference of the mediator profile or the IL-3 dose-
response relationship in cells from allergic or normal donors.
Effect ofIL-3onthe TimeCourse ofC5a-inducedResponses.
￿
Incontrast toIgE-dependent
basophil activation, C5a and other chemotactic agonists trigger a very rapid release
ofhistamine (3, 4). Fig. 3 showsthat IL-3 enhances the magnitude, but notthe time
course ofC5a-induced histamine release (top). Interestingly, sLT generation ofIL-3
treatedbasophilsalso occurs very rapidlyinparallel to degranulation(Fig. 3, bottom).
These experiments confirm that control cells do not generate sLT in response to
C5a over a period of 0-40 min.
Effect oftheSequenceofAddition ofthePeptidesandDependenceon Priming Time with IL-3.
Fig. 4 shows how the sequence ofaddition ofIL-3 and C5a influences mediator re-
lease. When IL-3 and C5a were added simultaneously, the enhancement ofhista-
mine release was 70% of that seen in primed cells. Addition of IL-3, even 10 min
after C5a, still induced a small, but significant increase in histamine release. How-
ever, a short preincubation with IL-3 was definitely required for efficient induction
ofsLT synthesis (Fig. 4, bottom). Fig. 5 shows that IL-3 priming for C5a-induced
leukotriene synthesis starts after a lag period of 1 min, becomes half-maximal at
2.5 min, and maximal after 5 min (top). Although this change in the mediator re-
lease pattern ofthebasophils is obviously a rapid process, primingforC5a-induced
sLT synthesis persisted for an observation period ofup to 2 h (data not shown). A
preincubation period with IL-3 is not required for an enhancement of':5a-induced
degranulation, but an optimal effect is reached also 5 min after priming with IL-3.
Mediator Release ofLeukocytes FractionatedbyPercollGradients.
￿
Histamine is a specific472
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FIGURE 3 .
￿
Time course of C5a-induced mediator re-
lease . Cellsfroman atopic donor were preincubatedwith
(closed circles) or without (open circles) 10-9MIL-3 for 10
min and then stimulated with C5a (10-8 M) for the time
indicated . Mean t SD (n = 3). (Top) percent histamine
release (total histamine = 69 t 1.1 ng/2.5 x 106 cells).
(Bottom) sLTproduction .Open symbols indicate the de-
tection limit forsLTwhen cells are exposed to IL-3 alone.
Identical kinetics are obtained with cells from normals .
marker for basophil degranulation, since it is not present in other leukocytes . By
contrast, sLT can also be generated by monocytes and eosinophils directly (6, 13),
or through LTA4 released by activated neutrophils (20) . Since monocytes, neutro-
phils, and eosinophils, in addition to basophils, all possessC5a receptors, the possi-
bility of an alternative source of the sLT had to be considered . Whole leukocytes
FIGURE 4 .
￿
Role of sequence of addition of IL-3 and C5a . Cells
are incubated as follows : (Open) control buffer 10 min, then C5a
(10-8 M) 20 min. (Filled) IL-3 (10 ng/ml) 10 min, then C5a 20
min . (Hatched) Control buffer 10 min, then IL-3 andC5a simul-
taneously for 20 min . (Dots)C5a 10 min, then IL-3 20 min . (Top)
Histamine release after subtraction of spontaneous release (total
histamine = 133 t 1.2 ng/2 .5 x 10 6 cells) . (Bottom) sLTproduc-
tion . The open column (C5a alone) represents the detection limit
for sLT Results of three experiments performed with cells from
an atopic donor areshown(mean t SD) . Results ofexperiments
with cells from both atopic and normalswere similar, except that
in some cases sLT generation was below detection limit for the
latter two conditions .60
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FIGURE 5.
￿
Effect of the preincubation time with IL-3 upon
C5a-induced mediator release. The cells were exposed to IL-3
(1 nM) andthe time before the addition ofC5a(10-s M) was
varied as indicated in the abscissa. All the cells were incubated
c5o
￿
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￿
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￿
2
￿
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￿
during 30 min after addition of IL-3, the only variable being
alone
￿
the time between the addition of the two peptides. C5aalone
is shown for comparison (columns). (Top) sLTgeneration. Each
data point represents asingle determination. The column for
sLT generation with C5aalone represents the detection limit
for sLT. (Bottom) Histamine release after subtraction of spon-
taneous release (total histamine = 124 t 3.4 ng/2.5 x 106
cells). The mean of triplicates is shown.
C5a 0 1 2 3 4 5 6 7 8 9 10
alone
￿
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obtained after dextran sedimentation of erythrocytes were fractionated by centrifu-
gation through Percoll gradients and experiments as described in Fig. 1 were per-
formed . Each leukocyte fraction was examined by FACS using monoclonal markers
forT cells, B cells, monocytes, neutrophils, and NK cells and examined by micros-
copy in May-Grunwald stained cytocentrifuge samples. In addition, the total hista-
mine content of the cell fractions was determined as a marker for basophils. The
results of a typical experiment are shown in Table I. A very high amount of sLT
was generated by fraction 4, which contained 40 To unstainedcells by FACS analysis
corresponding to 35To basophils by morphological criteria, the remaining con-
taminating cells being exclusively small lymphocytes (mainly T cells). Fraction 1,
TABLE I
Total Histamine Content andsLT Generation ofLeukocytes
Fractionated by Percoll Gradient
" Percent of Leu-M3' cells determined by FACS analysis .
l Percent of neutrophils by FACS analysis (Leu-lla' in PMN right angle light scatter
window).
s Histamine content of cell lysate.
II sLT generated by sequential stimulation ofleukocytes with IL-3 (1 nM) andC5a(10 nM).
Cell fractions
Percent
monocytes'
Percent
neutrophilsl
Histamine contents
(ng/2.5 x 106 cells)
sLTN
(pg/2.5 x 106 cells)
Unfractionated cells 21 50 87 1,264
Fraction
1 (<1 .060) 74 <3 9 <100
2 (1 .060/1.065) 36 <3 7 <100
3 (1 .065/1.070) 7 <3 102 3,200
4 (1 .070/1.075) <2 <3 1,612 32,100
5 (>1 .075) <2 85 30 137474
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which washighly enriched in monocytes and was contaminated exclusively by large
lymphocytes, generatedno sLT afterstimulation with C5a with or without preincu-
bation with IL-3, indicating that monocytesdo not produce sLTunder thesecondi-
tions. Eosinophils, for which no mAb was avaiable, were only found in fraction 5
(7 17o by microscopy), and did not appear to contribute to the sLT yield. The extent
of histamine release induced by C5a with or without IL-3 pretreatment was iden-
tical in unfractionated cells andin the differentcell fractions (datanot shown). Taken
together these resultsindicate that the basophil was the source ofsLT generatedunder
the presentexperimental conditions, andthat IL-3 effects thebasophil response directly,
presumably through specific receptors.
Discussion
This study demonstrates that the cytokine IL-3 at low concentrations profoundly
modifies themediator release profileof basophils stimulated with the anaphylatoxin
C5a. IL-3 enhanced the responsiveness of basophils to C5a. An enhancement of
histamine release was observed in all atopic or normal donors, while IL-3 alone did
not induce degranulation in most cases. More remarkably, IL-3 pretreatment ren-
dered the basophils capable of generating very large quantities of LTC4 in response
to C5a. Since neither IL-3 nor C5a, even at abnormally high concentrations, in-
duced sLT production, it appears that the effect observed is not due to a synergism
of threshold effects of two stimuli. Thus, IL-3 not only enhances the basophil re-
sponse but qualitatively changes the response pattern to a second signal. The quan-
tities of LTC4 formed were remarkable since they averaged 50 pg LTC4 per nano-
gram ofcellular histamine content. This meansthat thefew basophilsnormally present
in 1 ml of blood generate nanogram quantities of sLT within a few minutes after
triggering of primed cells with C5a. To our knowledge there is no other condition
or cell type capable of generating sLT at such a high rate.
Priming for C5a-induced sLT synthesis occurs at low IL-3 concentrations. The
ED5o of 0.2-0.4 U IL-3/ml is comparable to that required for the stimulation of
proliferation of CML leukocytes (1 U is defined as the ED5o in this assay). It is
remarkable that the priming of mature basophils occurs at 1/100th the concentra-
tion of IL-3 that is necessary to induce colony formation in bone marrow cultures.
This bioactivity is detectable at 3-10 U/ml andreaches amaximum at 100-300U/ml
(Fagg, B., Sandoz, Switzerland, personal communication). It is therefore conceiv-
able that the priming effect described here is the major physiological function of
this cytokine.
Chemotactic factor-induced LTB4 (14) and platelet-activating factor (PAF) (15)
synthesis in neutrophils requires 60-90 min preincubation ofthe cells with granulo-
cyte/macrophage CSF (GM-CSF). In contrast, C5a-induced sLT synthesis occurs
very rapidly after exposure to IL-3, starting at 1 min, with optimal effects at 5 min.
This change in responsiveness appears to be long lasting, as it is still apparent 2 h
after IL-3 exposure. These observations allow some speculations about the mecha-
nism of priming by IL-3 . The rapid onset suggests that IL-3 priming does not in-
volve gene expression and de novo synthesisofaregulatory proteinofphospholipase(s)/
lipoxygenase activation (22, 23). On the other hand, most known second messengers
are formed only transiently after interaction of a ligand with its receptors. TheyKURIMOTO ET AL.
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may be involved in signal transduction to IL-3 binding, but can notexplain the main-
tenance of the primed state. Better candidates for the effect of IL-3 are a rapid but
irreversible modification (i.e., phosphorylation), or translocation, ofaregulatory pro-
tein necessary, but not sufficient for lipid mediator synthesis (24) . Obviously, sLT
synthesis and degranulation are separately regulated cell responses, but the second
messengers responsible for each function remain to be defined. A study about the
mechanism by which IL-3 "couples"the C5aresponse to the lipid mediator synthesis
pathway should also give some insight into the regulation of the two cell responses.
Our work is related to two recent independent studies, which also demonstrate
an effect of IL-3 upon histamine release (25, 26). From experiments on leukocytes
incubated in 50% D20, Haak-Frendscho et al. (25) proposed that IL-3 is an his-
tamine-releasing factor. In contrast, our study indicates that IL-3 is devoid of di-
rect releasing activity. Preactivation of basophils in vivo, or e.g., as a consequence
of complement activation during blood collection, may explain the borderline re-
lease induced by IL-3 alone in some cell batches (Figs. 1 and 2), since a small en-
hancement of histamine release occurs even when IL-3 is the second signal (Fig.
4). Consistent with our study, Hiraiet al . (26) observed no histaminerelease by IL-3
alone, but an enhancement of degranulation was found after triggering with anti-
IgE or FMLP We also find an enhancement ofhistaminereleaseinduced by different
IgE-dependent and-independent basophil agonists, buteven forthese stimuli, which
by themselves are able to induce LTC4 synthesis, IL-3 affects sLT synthesis much
more strongly as compared with the modest increase in degranulation (Kurimoto,
Y ., et al., manuscript in preparation). Finally, there are several reports implicating
mostly undefined cell derived factors in basophil histamine release (27-39). It re-
mains to be better defined, whichcytokines otherthan IL-3 affect basophil mediator
release by themselves or in combination with other basophil agonists, and if only
degranulation or the generation of lipid mediators, or both, are affected.
There are similarities between the effects of GM-CSF on PMN and of IL-3 on
basophils. GM-CSF augments superoxide production in PMN (10, 11) and IL-3 en-
hances granule release in basophils. Thus, these two factors enhance the normal re-
sponses of the mature effector cells. More importantly, we show that they are both
required for the induction of lipid mediator synthesis by C5a. This work extends
our previous observations (14, 15) to the more general concept, that a major func-
tion of hematopoietic growth factors is to "prime" certain mature inflammatory cells
for lipid mediator synthesis, after triggering with agonists that by themselves are
insufficient to elicit such aresponse. As already indicated, however, theprimingtime
needed for C5a-induced sLT production is short, and therefore the mechanisms of
action of thecytokinesin PMNandbasophilsmaybe different. Thetarget cell profile
of the two cytokines seems also different. There is an abundant recent literature
about the effects of GM-CSF upon the function of a variety of mature leukocytes,
including neutrophils, monocytes, macrophages, and eosinophils (e.g., 9-12), while
almost nothing is known about an effect of IL-3 upon inflammatory effector cells
(16). Ourcell fractionation studiesindicate that the basophil is the source sLT gener-
ated by IL-3 and C5a, and that othercell typeslike monocytes, eosinophils, or neu-
trophils do not produce sLT undertheseconditions. Also, IL-3 does not primeneu-
trophils for chemotactic factor-induced LTB4 and PAF synthesis (Dahinden, C. A.,4'76
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unpublished observations), in contrast to GM-CSF (14, 15). Therefore, IL-3 seems
to be relatively basophil specific, at least as far as C5a-induced mediator release is
concerned.
In summary, we find that a product of the specific immune system (IL-3) pro-
foundly affects the effector function of mature basophils. The in vivo relevance of
this finding remains to be established. Possibly, the lipid mediators generated after
triggering of IL-3-primed basophils are of importance in the pathogenesis of
immediate-type hypersensitivity reactions, late-phase reactions, shock syndromes,
and inflammation, while consequences ofthe enhancement of degranulation areless
certain. The large quantities of sLT formed means that the biological effects of lipid
mediators may be about 50 times stronger than that of all the histamines stored in
the granules, since sLT are -1,000 timesmore potent that histamine on most target
tissues (6). Also, IL-3 primingofbasophils may not only enhance but even qualita-
tively change the pathophysiological consequences of complement activation, since
the biological effects of sLT and histamine do not totally overlap (6). Finally, the
fact that low concentrations of IL-3 are sufficient to modify the basophil response
indicates that such an effect could easily take place in the microenvironment of an
inflammatory reaction. In contrast, higher concentrations are needed to induce
proliferation of leukocyte progenitors, and'it is not known if enough endogenous
IL-3 can reach the target tissue by the blood stream, or ifit can be generatedlocally
in the bone marrow during an immune response. These arguments support the hy-
pothesis that IL-3 is an important component in inflammatory reactions.
Summary
The anaphylatoxin C5a is a potent trigger forbasophil degranulations, but in con-
trast to IgE-dependent basophil activation, it does not result in the synthesis of
sulfidoleukotrienes (leukotriene C4/D4/E4). Thus, degranulation and the generation
of lipid mediators are separately regulated cellular responses. Exposure of human
blood basophils to the cytokine IL-3 alone does not induce the release of histamine
in cells from most donors and never leads to the generation of LTC4, indicating that
IL-3 is not a direct agonist for basophil mediator release. However, preincubation
of basophils with IL-3 enhances the degranulation response to C5a. Most impor-
tantly, IL-3 "primes" basophils to release large amounts of leukotriene C4 afterchal-
lenge with C5a (mean of 50 gp LTC4 per nanograms cellular histamine), while nei-
ther peptide alone is capable of inducing the formation of bioactive lipids. This effect
is dose dependent, occurring at IL-3 concentrations considerably lower than are re-
quired to stimulate the growth of bone marrow progenitor cells. IL-3 affects the ex-
tent but not the time course of basophil degranulation, and leukotriene release of
cells sequentially exposed to IL-3 and C5a occurs very rapidly concomitant with
degranulation. A preincubation of the basophils with IL-3 is strictly required for
C5a-induced LTC4 synthesis, but not for an enhancement of degranulation.
Priming for C5a-induced lipid mediator generation occurs rapidly after exposure
of the cells to IL-3, starting at 1 min and reaching maximal effects at 5 min, but
this altered state of responsiveness is relatively long lasting. Cell fractionation studies
indicate that the basophil is the source of lipid mediators and that IL-3 affects the
basophil response directly. This study demonstrates that IL-3 is a potent modifierKURIMOTO ET AL.
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ofeffector functions ofmature basophils; this is possibly ofgreater in vivo significance
than its growth factor properties. The large amounts of LTC4 formed after trig-
gering of IL-3-primed basophils may not only enhance but also qualitatively change
the pathophysiological consequences of complement activation, and this might be
important in the pathogenesis of immediate type hypersensitivity reactions, shock
syndromes, and inflammation.
Receivedforpublication 8 March 1989 and in revisedform 25 April 1989.
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